Study guide

1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

Key Takeaways Explain This Topic AI

In 2024, the USPSTF lowered the recommended initiation age for biennial screening mammography from 50 to 40 years for all average-risk cisgender women and individuals assigned female at birth through age 74.

High-risk assessment models, such as the Tyrer-Cuzick (IBIS) model, identify individuals who qualify for annual supplemental screening breast MRI beginning at age 25–30 (lifetime breast cancer risk ≥20%–25%, BRCA pathogenic mutation, or mantle chest radiation between ages 10 and 30).

Diagnostic breast imaging differs fundamentally from screening: diagnostic mammography incorporates customized spot compression and magnification views paired with targeted ultrasound to evaluate focal clinical signs or abnormal screening findings.

Targeted breast ultrasound is the mandatory first-line imaging modality for palpable breast masses in women younger than 30 years and pregnant/lactating patients, avoiding ionizing radiation and reliably distinguishing simple cysts from solid neoplasms.

BI-RADS categories guide clinical decision-making: BI-RADS 3 requires 6-month short-interval surveillance, while BI-RADS 4 and 5 necessitate image-guided core needle biopsy; spontaneous, unilateral, uniductal nipple discharge requires diagnostic imaging and surgical duct excision to rule out intraductal papilloma or carcinoma.

Last updated: October 2026

Clinical Breast Examination & Breast Self-Awareness

Evaluating breast health requires systematic clinical inspection and palpation, combined with patient education regarding normal breast anatomy.

Clinical Breast Examination (CBE) Technique

A standardized CBE begins with visual inspection in four sequential postural positions:

  • Arms resting relaxed at sides
  • Arms elevated directly overhead
  • Hands pressed firmly against iliac crests (contracting pectoralis major)
  • Torso leaning forward from waist

Inspect for asymmetries, contour changes, erythema, dimpling, nipple retraction, scaling, or peau d'orange (cutaneous lymphatic obstruction). Palpation is conducted supine with the ipsilateral arm behind the head. Using the pads of the middle three fingers, apply light, medium, and deep circular pressure in a vertical strip pattern —from clavicle to inframammary fold, and sternum to mid-axillary line, including the axillary tail of Spence . Bilateral axillary, infraclavicular, and supraclavicular lymph node basins must be palpated with the patient seated.

Breast Self-Awareness vs. Monthly Breast Self-Exam (BSE)

Major clinical guidelines have abandoned structured monthly breast self-examinations. Trials showed rigid monthly BSE did not decrease breast cancer mortality but doubled benign biopsies and heightened distress. Current consensus (ACOG, ACS) emphasizes breast self-awareness : educating women on their baseline breast appearance and texture, and encouraging prompt clinical evaluation if a new palpable mass, focal thickening, spontaneous nipple discharge, or skin retraction arises.

Screening Mammography Guidelines Across Organizations

Guidelines for average-risk women reflect growing evidence regarding breast cancer incidence in women in their 40s:

Organization Initiation Age Screening Frequency Cessation Age

USPSTF (2024 Update) Age 40 (Lowered from 50 in April 2024) Biennial (every 2 years) Age 74 (Evidence insufficient for ≥75)

ACOG (2024 update) Begin at age 40 Annual or biennial (shared decision-making) Continue until at least age 75 , then individualize by health and life expectancy

American Cancer Society (ACS) Choice at 40–44; recommend at age 45 Annual ages 45–54; transition to biennial or continue annual at ≥55 Continue as long as overall health is good and life expectancy is ≥ 10 years

Screening vs. Diagnostic Mammography & Digital Breast Tomosynthesis (DBT)

Screening Mammography: Standard two-view assessment per breast—craniocaudal (CC) and mediolateral oblique (MLO)—performed on asymptomatic women.

Diagnostic Mammography: Indicated to evaluate abnormal screening exams or clinical signs (palpable lump, focal pain, skin retraction, spontaneous discharge). Incorporates spot compression, magnification views, and on-site radiologist interpretation.

Digital Breast Tomosynthesis (3D Mammography / DBT): Captures multiple low-dose X-ray projections across an arc to reconstruct thin 1 mm slices. DBT reduces false-positive recall rates by ~15% and increases invasive cancer detection by 30%–40%, particularly in heterogeneously or extremely dense breasts (BI-RADS breast density categories C and D).

  • High-Risk Stratification & Supplemental Breast MRI
  • Risk Assessment Models

Gail Model (BCRAT): Estimates 5-year and lifetime risk based on age, age at menarche, age at first live birth, first-degree relatives with breast cancer, and prior benign breast biopsies (especially atypical hyperplasia). High risk is defined as a 5-year risk ≥1.67% or lifetime risk ≥20%. Limitations: Omits paternal family history, second-degree relatives, and age of diagnosis in relatives.

Tyrer-Cuzick (IBIS) Model: Incorporates comprehensive multigenerational maternal and paternal pedigrees, bilateral breast cancers, ovarian cancer, age of onset, dense breasts, Ashkenazi Jewish heritage, and exogenous hormones. Highly sensitive for hereditary risk.

Criteria for Supplemental Screening Breast MRI

Annual contrast-enhanced breast MRI (typically alternating every 6 months with screening mammography, beginning at age 25–30 ) is recommended for:

  • Lifetime breast cancer risk ≥ 20% to 25% based on pedigree models (e.g., Tyrer-Cuzick)
  • Known pathogenic BRCA1 or BRCA2 mutation (or TP53, PTEN, CDH1, STK11)
  • Untested first-degree relative of a known BRCA mutation carrier

History of mantle or chest radiation therapy between ages 10 and 30 (screening starts 8–10 years post-radiation or at age 25, whichever is later)

Diagnostic Imaging Modalities & BI-RADS Classification

Modality selection depends on patient age and clinical presentation:

Age < 30 Years: Targeted breast ultrasound is the primary first-line modality. Young women possess dense fibroductal tissue that impairs mammographic sensitivity, and their tissue is more radiosensitive. Mammography is added only if ultrasound demonstrates suspicious features.

Age ≥ 30 Years: Diagnostic mammography PLUS targeted ultrasound is the standard initial imaging workup for a palpable breast mass.

Pregnancy / Lactation: Targeted ultrasound is first-line; mammography with abdominal shielding is safe if malignancy is suspected.

BI-RADS Categories & Clinical Management Directives

BI-RADS Category Assessment Malignancy Risk Clinical Management Directive

0 Incomplete N/A Recall for additional imaging: diagnostic views, ultrasound, or prior films.

1 Negative Essentially 0% Continue routine screening interval.

2 Benign Finding Essentially 0% Continue routine screening (simple cyst, calcified fibroadenoma).

3 Probably Benign < 2% Short-interval follow-up: Unilateral imaging at 6 months, then every 6–12 months for 24–36 months to confirm stability.

4 Suspicious Abnormality 2% to 95% Tissue diagnosis required: Image-guided core needle biopsy.

5 Highly Suggestive of Malignancy > 95% Tissue diagnosis required: Urgent core needle biopsy with prompt surgical oncology referral.

6 Known Biopsy-Proven Malignancy 100% Definitive surgical excision and oncologic therapy.

Note

A clinically suspicious palpable mass (firm, fixed, irregular) requires tissue biopsy even if mammography and ultrasound yield a BI-RADS 1 or 2 result. Imaging never supersedes clinical suspicion—this is the core tenet of the "Triple Assessment" (CBE, imaging, histology).

  • Clinical Triage of Palpable Breast Masses & Nipple Discharge
  • Differential Diagnosis of Palpable Masses

Fibroadenoma: Most common benign solid tumor in women aged 15–35. Characteristics: well-circumscribed, mobile, nontender, rubbery mass, usually 1–3 cm. Hormone-responsive (may enlarge during pregnancy or luteal phase).

Breast Cyst: Fluid-filled round cavity common in perimenopausal women (ages 35–50). Characteristics: smooth, fluctuant, tender, acute onset, fluctuating with menses. Aspiration confirms diagnosis if symptomatic; clear fluid without residual mass requires no further workup.

Malignancy (Invasive Carcinoma / DCIS): Hard, fixed, nontender mass with irregular borders, often accompanied by skin dimpling, nipple retraction, or hard, matted axillary lymphadenopathy.

Evaluation and Triage of Nipple Discharge

Physiologic Discharge: Bilateral, multiductal, non-spontaneous (expressible only on manipulation); milky, clear, yellow, green, or brown; guaiac-negative. Causes: pregnancy, lactation, hypothyroidism (TRH stimulates prolactin), prolactinoma, medications (antipsychotics, SSRIs, metoclopramide, verapamil). Diagnostic workup: serum hCG, prolactin, TSH, and medication audit.

Pathologic Discharge: Spontaneous, unilateral, uniductal (emerges from a single duct orifice); bloody, serosanguineous, or watery; or associated with a palpable mass or age ≥40. Causes: Intraductal papilloma (>50% of cases; benign lactiferous duct polyp), duct ectasia, ductal carcinoma in situ (DCIS; 10%–15%), or invasive ductal carcinoma. Diagnostic workup: Diagnostic mammography with subareolar and targeted ultrasound, followed by surgical referral for terminal duct excision (microdochectomy).

Fibrocystic Change, Mastalgia & Breast Surgery History

Fibrocystic change: Cyclic, bilateral tenderness and lumpy nodularity, worst in the upper outer quadrants during the late luteal phase. Nonproliferative changes do not raise cancer risk; atypical ductal or lobular hyperplasia raises lifetime risk about four-fold and should prompt high-risk counseling.

Mastalgia: Cyclic pain is hormonal and usually bilateral; noncyclic focal pain deserves diagnostic imaging of the painful area. First-line care is a well-fitted support bra, reassurance, and topical NSAIDs such as diclofenac gel. Danazol (the only FDA-approved agent, androgenic) and tamoxifen are reserved for severe refractory pain.

Breast augmentation: Implants do not change screening age; mammography adds implant-displacement (Eklund) views. For silicone implants, FDA labeling advises ultrasound or MRI to look for silent rupture 5–6 years after placement and every 2–3 years thereafter. A new, late seroma or swelling a year or more after a textured implant suggests breast implant–associated anaplastic large cell lymphoma (BIA-ALCL): obtain ultrasound-guided aspiration with CD30 immunohistochemistry.

Reduction mammoplasty: May reduce milk supply; postoperative fat necrosis and scarring can mimic a mass on exam or imaging, so compare with prior studies.

Loading diagram... Clinical Triage of Palpable Breast Masses & Nipple Discharge